vs
Side-by-side financial comparison of BayCom Corp (BCML) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -0.8%, a 27.3% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -25.7%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-15.8M). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs -15.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BCML vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $18.7M |
| Net Profit | $6.9M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -6.9% |
| Net Margin | 26.5% | -0.8% |
| Revenue YoY | 9.4% | -25.7% |
| Net Profit YoY | 12.1% | 97.6% |
| EPS (diluted) | $0.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | — | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $24.7M | $18.7M | ||
| Q1 25 | $24.3M | $50.9M | ||
| Q4 24 | $23.7M | $38.1M | ||
| Q3 24 | $25.6M | $33.4M | ||
| Q2 24 | $23.8M | $25.1M | ||
| Q1 24 | $24.5M | $41.5M |
| Q4 25 | $6.9M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $6.4M | $-154.0K | ||
| Q1 25 | $5.7M | $23.5M | ||
| Q4 24 | $6.1M | $18.9M | ||
| Q3 24 | $6.0M | $5.7M | ||
| Q2 24 | $5.6M | $-6.5M | ||
| Q1 24 | $5.9M | $13.8M |
| Q4 25 | 36.6% | — | ||
| Q3 25 | 26.3% | — | ||
| Q2 25 | 35.3% | -6.9% | ||
| Q1 25 | 31.6% | 44.4% | ||
| Q4 24 | 34.2% | 46.4% | ||
| Q3 24 | 32.4% | 12.3% | ||
| Q2 24 | 31.9% | -33.7% | ||
| Q1 24 | 33.3% | 28.1% |
| Q4 25 | 26.5% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 25.8% | -0.8% | ||
| Q1 25 | 23.4% | 46.2% | ||
| Q4 24 | 25.9% | 49.6% | ||
| Q3 24 | 23.5% | 17.2% | ||
| Q2 24 | 23.6% | -26.0% | ||
| Q1 24 | 24.0% | 33.3% |
| Q4 25 | $0.63 | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.58 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $0.54 | — | ||
| Q2 24 | $0.50 | — | ||
| Q1 24 | $0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $119.9M |
| Total Assets | $2.6B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M |
| Q4 25 | $338.6M | — | ||
| Q3 25 | $334.3M | — | ||
| Q2 25 | $330.6M | $119.9M | ||
| Q1 25 | $329.3M | $25.0M | ||
| Q4 24 | $324.4M | $-456.0K | ||
| Q3 24 | $321.7M | $-23.5M | ||
| Q2 24 | $315.3M | $-31.2M | ||
| Q1 24 | $314.2M | $-31.7M |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | $175.1M | ||
| Q1 25 | $2.6B | $98.5M | ||
| Q4 24 | $2.7B | $120.5M | ||
| Q3 24 | $2.6B | $139.0M | ||
| Q2 24 | $2.6B | $159.2M | ||
| Q1 24 | $2.6B | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-15.8M |
| Free Cash FlowOCF − Capex | $30.1M | $-15.8M |
| FCF MarginFCF / Revenue | 116.2% | -84.6% |
| Capex IntensityCapex / Revenue | 6.7% | 0.1% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | — | ||
| Q3 25 | $7.3M | — | ||
| Q2 25 | $6.4M | $-15.8M | ||
| Q1 25 | $9.3M | $-21.0M | ||
| Q4 24 | $30.4M | $-19.9M | ||
| Q3 24 | $9.6M | $-20.7M | ||
| Q2 24 | $7.7M | $-19.5M | ||
| Q1 24 | $5.1M | $-26.0M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | $-15.8M | ||
| Q1 25 | $9.1M | $-21.2M | ||
| Q4 24 | $28.7M | $-20.0M | ||
| Q3 24 | $9.4M | $-20.7M | ||
| Q2 24 | $7.4M | $-19.6M | ||
| Q1 24 | $3.9M | $-26.2M |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | -84.6% | ||
| Q1 25 | 37.6% | -41.6% | ||
| Q4 24 | 121.1% | -52.5% | ||
| Q3 24 | 36.6% | -62.1% | ||
| Q2 24 | 31.2% | -78.2% | ||
| Q1 24 | 16.1% | -63.1% |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 3.0% | 0.1% | ||
| Q1 25 | 0.6% | 0.2% | ||
| Q4 24 | 7.2% | 0.2% | ||
| Q3 24 | 1.0% | 0.1% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 4.7% | 0.3% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | -0.89× | ||
| Q4 24 | 4.96× | -1.05× | ||
| Q3 24 | 1.60× | -3.61× | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
